Replies to post #681 on Rezolute Inc. (RZLT)

[Whalatane]

From Grok
Comparison of Population in RZLT's Phase 2 RIZE Study and Phase 3 sunRIZE TrialRezolute, Inc. (Nasdaq: RZLT) is developing ersodetug (RZ358) for congenital hyperinsulinism (cHI), a rare condition causing persistent hypoglycemia.
The Phase 2 RIZE study (RZ358-606) was an open-label trial assessing safety, tolerability, and efficacy in pediatric patients with cHI.
The Phase 3 sunRIZE trial (RZ358-301) is a randomized, double-blind, placebo-controlled study evaluating efficacy and safety in a broader cHI population.
Below is a comparison of key population aspects based on publicly available trial data.Aspect
Phase 2 RIZE Study
Phase 3 sunRIZE Trial
Enrollment Size
22 patients (completed; exceeded initial target of 18–24)
62 patients (completed; exceeded target of ~56)
Age Range
=2 years to ~45 years (average age: 6.5 years; included 16 patients aged 2–6 years)
3 months to 45 years (preliminary data shows lower average ages than RIZE due to expanded eligibility)
Key Demographics
Primarily pediatric (young children predominant); diverse cHI subtypes with persistent hypoglycemia despite standard-of-care (SOC) therapies
Broader age spectrum, including infants; ~15% from U.S. sites; generally comparable to RIZE in baseline characteristics (e.g., hypoglycemia burden, cHI subtypes) except for younger ages
Inclusion Criteria
Patients =2 years with cHI inadequately controlled on SOC; focus on glycemic endpoints via continuous glucose monitoring
Patients =3 months with cHI and continued hypoglycemia on SOC; similar glycemic entry criteria but expanded to infants for broader applicability
Study Design Impact on Population
Open-label, sequential cohorts (3–9 mg/kg dosing); smaller size for proof-of-concept
Randomized (ersodetug 5/10 mg/kg vs. placebo); larger size for pivotal efficacy data; global sites (~20 centers in >12 countries)

Key InsightsScale: The sunRIZE trial enrolled nearly 3 times more patients than RIZE, reflecting Phase 3 requirements for statistical power in a rare disease setting.
Age Expansion: sunRIZE's inclusion of infants (=3 months) addresses a critical unmet need in very young cHI patients, who face higher risks; RIZE focused on older children but informed dosing for younger groups.
Comparability:
Preliminary sunRIZE data indicate similar baseline hypoglycemia severity and demographics to RIZE (e.g., persistent events despite SOC), supporting continuity in evaluating ersodetug's impact on primary endpoints like weekly hypoglycemia events. ( my emphasis )
Status: RIZE completed in 2022 with positive results (significant hypoglycemia reductions in nearly all participants). sunRIZE enrollment completed in May 2025, with topline data expected in December 2025.

This comparison highlights how sunRIZE builds on RIZE's foundational data while scaling and broadening the population for regulatory submission.

---------------------------------------
So the risks
P2 was open label and smaller ---- P3 blinded , slightly higher dose , wider age range and in 12 ? countries

Kiwi
ps
note

Whalatane
Re: Sagaponack post# 573
Thursday, August 21, 2025 2:15:06 PM
Post# of 682
Well I've owned this over a yr ...and have sold enough to cover my initial investments plus .
At this pt I'll just hold thru readout unless it grows to 20% of my portfolio ...where I'll automatically sell some .